Based out of research from the University of Massachusetts Amherst and from the vast prior literature, RNA4Tx is founded on the principle of applying mechanistic understandings, together with well-established approaches in chemical engineering, to develop wholly new approaches to manufacturing mRNA, CRISPR guide RNA, and emerging RNAs such as lncRNAs.
A key challenge in mRNA therapeutics is the presence of double stranded RNA impurities. While vaccines actually benefit from a small amount of the immune stimulation that these impurities can produce, even vaccines can suffer from too much contamination. Costly downstream purification is then essential (and expensive and yield-reducing).
RNA4Tx technologies aim to stop the production of these impurities during the initial step of manufacturing, eliminating the need for extensive purification.
An ounce of prevention is worth a pound of purification!
Craig Martin, Founder